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ABSTRACT
Current hypertension guidelines suggest various strategies to reduce blood pressure 
levels, thereby reducing cardiovascular events: combinations of drugs with different 
mechanisms of action, such as an angiotensin converting enzyme inhibitors (ACEIs) 
and a diuretic, are the cornerstone of the modern treatment of hypertension, also as 
initial therapy. Among ACEIs, zofenopril has been shown to be effective in the 
management of hypertension both as monotherapy and in combination with a diuretic: 
zofenopril/hydrochlorothiazide fixed dose combination is particularly useful to improve 
treatment adherence through simplification of treatment regimen. Moreover, thanks to 
the sulfhydryl group, zofenopril has some peculiar properties (higher lipophilicity and 
tissue penetration, lower bradykinin-dependent effect, higher affinity for, and more 
persistent binding to, tissue ACE, significant antioxidant effect), which may account for 
the cardio-protective effects of the drug demonstrated in both pre-clinical studies and 
randomized clinical trials. The positive impact of zofenopril on clinical outcomes has 
been extensively documented by the SMILE program, including several clinical trials in
patients with different conditions of myocardial ischemia treated with zofenopril: the 
results of the SMILE program, demonstrating the benefits of zofenopril vs. placebo and 
other ACEIs, emphasize the importance of a differentiated approach to patients with 
ischemic heart disease, based on a careful choice of the adopted agent, in order to 
improve the overall impact of pharmacological treatment on clinical outcomes.
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Background
Despite the substantial progress made in understanding the epidemiology, 
pathophysiology, and risk associated with hypertension (HTN) and the treatment 
strategies currently available to reduce blood pressure (BP), HTN remains a major 
preventable cause of cardiovascular disease (CVD) and all-cause death globally [1]. 
Available evidence demonstrates that BP lowering can substantially reduce 
premature morbidity and mortality. Meta-analyses of randomized clinical trials 
(RCTs) including several hundred thousand patients have shown that a 10-mmHg 
reduction in systolic BP (SBP) or a 5-mmHg reduction in diastolic BP (DBP) is 
associated with significant reductions in all major CV events by 20%, all-cause 
mortality by 10–15%, stroke by 35%, coronary events by 20%, and heart failure 
(HF) by 40%. These relative risk reductions are consistent, irrespective of baseline 
BP within the hypertensive range, level of CV risk, comorbidities (e.g., diabetes 
and chronic kidney disease [CKD]), age, sex, and ethnicity [1].
The 2018 European Society of Cardiology/European Society of Hypertension 
(ESC/ESH) hypertension guidelines have introduced many therapeutic novelties, aiming
at optimizing HTN treatment and improving BP control. The most important 
innovations include an earlier start of pharmacologic treatment (which is now 
recommended in patients with high normal BP and very high CV risk, as well as in 
patients with grade 1 hypertension and high or very high CV risk), lower BP targets (≤ 
130/80 mmHg in most patients, if tolerated, regardless of CV risk or comorbidities), and
a less conservative approach to old (≥ 65 years) and very old patients (> 80 years), with 
lower treatment thresholds (grade 1 hypertension [PAS 140–159 mmHg] in old fit 
patients), and lower BP targets (< 130–139 mmHg for old and very old patients, if 
tolerated) [1].
Another major novelty is that guidelines have abandoned the recommendation of 
monotherapy for treatment initiation, in favor of an initial dual drug combination in 
most patients, in order to minimize low adherence and therapeutic inertia, known to be 
the major causes of low BP control in the hypertensive population. Moreover, initial 
combination treatment results in reduced treatment discontinuation and a lower risk of 
CV events. Single pill combinations are recommended as the best choice for initiation 
of dual drug pharmacologic treatment in most patients, because reducing the number of 
pills to be taken daily improves adherence and increases the rate of BP control [1].
New guidelines continue to consider the main 5 drug classes — i.e., angiotensin 
converting enzyme inhibitors (ACEIs), angiotensin receptors blockers (ARBs), calcium 
channel blockers (CCBs), diuretics, and beta-blockers (BBs) — as the most suitable for 
treatment initiation and maintenance, because for each of them there is evidence of BP-
lowering effectiveness, protective effect vs. placebo and, in most trials and meta-
analyses, similar degree of protection in comparison studies. There are also data from 
randomized trials of CV protection by their combined use [1].
According to new guidelines, combinations of drugs with different mechanisms of 
action are the cornerstone of the modern treatment of HTN. Preferred combinations 
should comprise a blocker of the renin–angiotensin–aldosterone system (RAAS), with a 
CCB or a diuretic; these combinations have the advantage of being complementary, 
because both CCBs or diuretics activate the RAAS, which will be counteracted by their 
combination with a RAAS blocker. These combinations will also limit potential adverse
effects associated with diuretic or CCB monotherapy, reducing the risk of hypokalemia 
due to diuretics and the prevalence of peripheral edema due to CCBs [1].
In the context of the newly recommended main treatment strategy, guidelines have 
upgraded the use of an RAAS blocker with a CCB or diuretic not only because of the 
evidence of their protective effect in uncomplicated HTN or in the presence of HTN-
mediated organ damage (HMOD) or specific comorbidities, but also for their greater 
availability in single pill combinations [1].
The pharmacological blockade of the RAAS can be achieved with either inhibition of
the angiotensin converting enzyme (with ACEIs) or blockade of the angiotensin 
receptor (with ARBs): both classes are strongly recommended, because beyond their 
anti-hypertensive action, they reduce albuminuria more than other BP-lowering drugs 
and are effective at delaying the progression of diabetic and non-diabetic CKD. ACEIs 
and ARBs also appear to be effective in preventing or regressing HMOD, such as left 
ventricular hypertrophy and small artery remodeling, for an equivalent reduction in BP. 
Both drugs reduce incident atrial fibrillation (AF), which may be related to improved 
left ventricular (LV) function and more effective LV structural regression. Due to the 
huge body of trial-based evidence, ACEIs and ARBs are the pillar of antihypertensive 
therapy, playing a major role in both primary and secondary CV prevention [1].
The purpose of the present review is to summarize the current evidence supporting 
the effectiveness of ACEIs in terms of BP control and CV protection, with a focus on 
sulfhydrylic ACEIs in general, and zofenopril in particular, highlighting the peculiar 
pharmacological properties underlying its favorable efficacy profile.
The key role of ACEIs in HTN and CV protection 
Given the pivotal role of angiotensin II in the pathogenesis of CVD, ACEIs play a 
key role in HTN treatment: by blocking the conversion of angiotensin I to angiotensin 
II, they exert reno- and cardio-protective effects in addition to anti-hypertensive activity,
which makes them an excellent option for front-line management of HTN in patients 
with associated risk factors. Reduced BP with ACEI monotherapy is reported in 35–
70% of patients, whereas response rates > 80% in patients with mild to moderate HTN 
treated with an ACEI/diuretic combination have been reported. Moreover, this class of 
agents is associated with few metabolic adverse effects, both in monotherapy and in 
combination [2].
Thus, ACEIs have an unchallenged position among available antihypertensive drugs 
as first-step treatment of HTN: they are effective for uncomplicated HTN and 
asymptomatic HMOD [1], and are the preferred drugs for the treatment of many specific
conditions (AF/HF/post-stroke/post-myocardial infarction/PAD/CKD) [3].  
Activation of RAAS has long been implicated also in the pathogenesis of acute 
myocardial infarction (AMI), and its blockade through use of ACEIs has been shown to 
be beneficial in preventing major CV complications in several large, randomized, 
prospective, early and late intervention trials in patients with post-AMI [4].
Based on this evidence, ACEIs have been recognized as holding a key position in the
primary antihypertensive treatment strategy, as a part of initial combination therapy [1], 
as well as in the management of AMI, as an essential component of treatment of patients
with ST segment elevation anterior AMI, post-AMI LV dysfunction (LV ejection 
fraction [LVEF] < 40%), or those who have experienced HF in the early phase of AMI 
[5, 6].
Pharmacological properties of sulfhydrylic ACEIs: Which advantages for cardio-
protection?
After the discovery of captopril, the prototype of orally active ACEIs, several new 
ACEIs were developed and introduced into medical practice, differing in their chemical 
structure, functional groups (sulfhydryl in captopril and zofenopril, carboxyl in 
enalapril, phosphinyl in fosinopril), active moiety (some are prodrugs), potency, 
ancillary pharmacological actions, and pharmacokinetics [7]. 
Sulfhydrylic ACEIs have some peculiar aspects, contributing to their 
pharmacological properties: i) higher lipophilicity and tissue penetration; ii) lower 
bradykinin-dependent effect; iii) higher affinity and more persistent binding to tissue 
ACE (cardiac/renal/vascular); and iv) significant antioxidant effect [7].
The most recent sulfhydrylic ACEI to reach the European market was zofenopril, a 
highly lipophilic drug, characterized by increased oral absorption, an appreciable degree
of biliary excretion, and enhanced tissue penetration [7].
Zofenopril is unique in producing long-lasting and selective inhibition of heart tissue 
ACE, which is likely determined by the high efficiency with which the prodrug is taken 
up by heart tissue and promptly hydrolyzed by cardiac esterases to the active inhibitor 
carrying a sulfhydryl group, zofenoprilat [7], which is 6–10 times more potent than 
captopril, displaying an EC50 in the nanomolar range (1–8 nM) [8]. Compared to 
captopril, zofenopril produces a dose-dependent antihypertensive effect of longer 
duration (> 17 h) in animal models of hypertension [7].
The presence of an SH group grants peculiar cardio-protective properties to 
sulfhydrylic ACEIs: in vitro studies in experimental models of ischemia/reperfusion 
(I/R) demonstrated the cardio-protective properties of zofenopril, in terms of 
improvement of post-ischemic LV function (LVF), increased coronary flow, and 
reduced CK release, as well as reduced lipid peroxidation during reperfusion. Although 
these cardio-protective effects were observed with both zofenopril and captopril, 
zofenopril was more potent. In particular, in isolated perfused hearts, zofenopril 10–5 M 
exerted a greater effect than captopril in restoring cardiac function after I/R [9, 10].
In vivo animal studies confirmed the ability of zofenopril to prevent ischemic 
myocardial damage, as well as to reduce post-ischemic cardiac remodeling by 
suppressing the increase of both ventricular mass and volume [7]. 
The potential of sulfhydrylic ACEIs in scavenging radical oxygen species has been 
proposed as a co-causative factor in the cardio-protection exerted by this class of 
compounds [7]. This may be due to the fact that the SH group is a potent proton donor, 
exerting an important anti-oxidant activity; in this regard, the cardio-protective effect of 
zofenopril in murine and swine models of myocardial I/R injury was associated with an 
increase in hydrogen sulfide (H2S) bioavailability [10]. An additional mechanism by 
which H2S confers cardio-protection against I/R injury and pressure-overload HF is 
through its ability to enhance endothelial nitric oxide synthase (eNOS) activity and 
thereby increase myocardial nitric oxide (NO) bioavailability [10]. In vivo studies 
demonstrated that the modulation of H2S by zofenopril represents an additional 
beneficial mechanism unrelated to ACE-inhibition [11]. Experimental data suggest 
therefore that zofenopril may provide a double advantage, deriving from both ACE-
inhibition and increased H2S bioavailability (Fig. 1) [10]: by inhibiting myocardial ACE
activity, zofenopril reduces the conversion of angiotensin I to angiotensin II and 
increases the levels of bradykinin. Bradykinin, through stimulation of endothelial B2 
receptors, promotes the release of NO, prostacyclin, and endothelium-derived 
hyperpolarizing factor (EDHF), as well as eNOS activation, leading to increased levels 
of NO [10].
The increased NO availability induced by the activation of both these pathways may 
account for the greater benefits seen with zofenopril compared with other ACEIs; this 
has been confirmed in vitro by measuring the stimulation of NO release by endothelial 
cells induced by captopril, enalapril, or zofenopril, the latter being much more effective 
than the comparators [12]. Similarly, zofenoprilat was shown to be more effective than 
captopril, lisinopril, and enalaprilat in reducing endothelin-1 (ET-1) secretion from 
cultured human vascular endothelial cells (HUVECs), an effect most likely due to the 
sulfhydryl-related scavenging capability and the consequent decrease in NO inactivation
by endogenous oxidants [13].
The beneficial effect of NO in terms of cardio-protection might also depend upon its 
role in ischemic preconditioning, a phenomenon by which a prolonged episode of 
ischemia paradoxically induces much less injury than expected if it occurs after a brief 
“preconditioning” episode of ischemia: indeed, it has been demonstrated that new-onset 
angina preceding AMI is associated with lower release of markers of cell necrosis, and 
improved contractile recovery after thrombolysis [14].
Consistent with the role of NO in inducing preconditioning, pharmacological 
preconditioning may be achieved through NO donors by using chronic nitrate therapy, 
as documented by the results of the Global Registry of Acute Coronary Events: in this 
large multinational registry, including 52,693 patients from 123 centers in 14 countries, 
chronic nitrate use was associated with a shift away from ST segment elevation MI in 
favor of non-ST segment elevation MI-acute coronary syndrome, and with less release 
of markers of cardiac necrosis. These findings suggest that in chronic nitrate users, 
acute coronary events may develop to a lesser extent [15].
It is now recognized that NO exposure before ischemia may act as a potent 
preconditioning mimetic and cardio-protectant, and it may represent the basis of 
potential infarct-sparing strategies; activation of NO synthase or production of NO can 
be obtained pharmacologically with exogenous agents able to trigger this cascade [16], 
such as the SH-containing ACEI zofenopril.
Clinical efficacy of zofenopril in complicated patients: The SMILE project 
The positive impact of the cardio-protective effect of zofenopril on clinical outcomes
has been extensively documented by the SMILE project, including several clinical trials
in patients with different conditions of myocardial ischemia treated with zofenopril 
(Table 1) [17–21].
The 5 double-blind, randomized, parallel-group SMILE studies [17–21] compared 
the efficacy and safety of zofenopril with that of placebo (SMILE Pilot [17], SMILE-1 
[18] and SMILE-3 [20]), lisinopril (SMILE-2) [19], or ramipril (SMILE-4) [21] in 
European men and non-pregnant women with AMI. Patients included in the studies 
were those with the following: (1) an early AMI (< 24 h), not eligible for thrombolytic 
therapy because of late admission to the intensive care unit or with contraindication to 
systemic fibrinolysis (SMILE-1) [18]; (2) a confirmed diagnosis of AMI and a prior 
thrombolytic treatment within 12 h of the onset of clinical symptoms of AMI (SMILE-
2) [19]; (3) a recent AMI (within 6 ± 1 weeks) with preserved LVEF (> 40%), treated 
with a thrombolytic treatment and with ACEIs (SMILE-3) [20]; and (4) an early MI (< 
24 h), either treated with thrombolysis or not, with primary percutaneous transluminal 
angioplasty or coronary artery by-pass graft, and with clinical and/or echocardiographic 
evidence of LV dysfunction (SMILE-4) [21].
The antioxidant properties of zofenopril and its ability to modulate the availability of 
NO and the vascular tone at the coronary level may be responsible for the anti-ischemic 
effect of the drug originally described in the SMILE Pilot Trial, in which the outcome of
post-MI patients was significantly improved by the treatment with zofenopril compared 
to placebo [17]. In-hospital and long-term consequences of treatment with zofenopril 
initiated within 24 h from the onset of symptoms were compared with those of standard 
treatment in this open-label trial involving 204 patients with AMI not undergoing 
thrombolytic treatment. The in-hospital incidence of acute LV failure and ventricular 
arrhythmias decreased by 63% and 39%, respectively, among zofenopril-treated 
patients, who also reported fewer angina episodes both acutely (68% reduction) and 
over the long term (56% reduction). LV size decreased and LVEF increased in patients 
who received zofenopril, and the improvement was greater among patients with poorer 
ventricular function (EF < 40%). These results suggest that early administration of 
zofenopril may be effective in patients with AMI, particularly when the event is 
complicated by clinical signs or evidence of LVD [17].
The benefits of zofenopril for patients with AMI and LVD were confirmed by the 
SMILE-1 study, in which zofenopril was able to improve prognosis during the very 
early phase (i.e., within 48 h from the onset of symptoms) and the mid phase of the 
disease (i.e., after 6 weeks of double-blind treatment), as well as over 1 year of 
treatment [18]. Among 1556 enrolled patients within 24 h of the onset of symptoms of 
anterior AMI and randomly assigned in a double-blind fashion to receive either placebo 
(784 patients) or zofenopril (772 patients) for 6 weeks, the cumulative reduction in the 
risk of death or severe congestive HF was 34% at 6 weeks (46% for severe congestive 
HF and 25% for death). The beneficial effect of short-term treatment with zofenopril 
was maintained over time: after 1 year of observation, the mortality rate was 
significantly lower in the zofenopril group than in the placebo group (10.0% vs. 14.1%, 
29% risk reduction; p = 0.011). These results confirmed the benefits of early treatment 
with zofenopril, significantly improving both short-term and long-term outcomes when 
started within 24 h of onset of anterior AMI and continued for 6 weeks [18].
The SMILE-2 study, a phase III, double-blind, parallel-group, multicenter study 
comparing the safety and efficacy of zofenopril (30–60 mg/day) and lisinopril (5–10 
mg/day), starting within 12 h of completion of thrombolytic therapy and continuing for 
42 days, in 1024 thrombolyzed patients with AMI, demonstrated that both zofenopril 
and lisinopril are safe and associated with a rather low rate of severe hypotension when 
given in accordance with a dose-titrated scheme. The incidence of drug-related severe 
hypotension was slightly but significantly lower with zofenopril than with lisinopril 
(6.7% vs. 9.8%, 2-tailed p = 0.048). These findings could have a positive clinical impact
and increase the proportion of patients with AMI who can be safely treated with ACEIs 
[19].
The cardio-protective role of zofenopril when given to patients with normal LVF 
after AMI were confirmed by the SMILE-3 Ischemia Study, which demonstrated a 
significant reduction of the ischemic burden (defined as significant ST-T abnormalities 
on ambulatory electrocardiography, electrocardiography abnormalities or symptoms of 
angina during standard exercise test, recurrence of MI, and need for revascularization 
procedures for angina) in 349 post-MI patients with preserved LVF (LVEF > 40%) 
treated for 6 months with zofenopril 30 to 60 mg (n = 177) or placebo (n = 172) 
according to a double-blind, randomized study design [20]. The primary endpoint 
(global ischemic burden) occurred in 20.3% of zofenopril-treated and 35.9% of placebo-
treated patients (44% risk reduction, p = 0.001), despite no differences in BP control, 
LVF, and concomitant therapy. The rate of major CV events was reduced in patients 
treated with zofenopril, with a lower rate of development and progression of congestive 
HF. The results of the SMILE Ischemia study extend the benefits of zofenopril in terms 
of cardio-protection and prevention of coronary events from the early to the late phase 
of MI [20].
The difference between zofenopril and other ACEIs in post-MI patients complicated 
with LVD (clinical signs of HF or EF < 45%) was investigated by the SMILE-4 study, 
showing a higher cardio-protective effect of zofenopril compared to ramipril (both in 
combination with acetylsalicylic acid [ASA]). The 1-year combined occurrence of death
or hospitalization for CV causes was significantly reduced by zofenopril vs. ramipril 
(odds ratio [OR]: 0.70; p = 0.028), as a result of a decrease in CV hospitalization (OR: 
0.64; p = 0.06) [21]. Furthermore, the results of the SMILE-4 trial showed that 
differences in clinical efficacy may exist when different ACEIs are combined with ASA,
demonstrating a more favorable impact of zofenopril than ramipril on major CV events 
and in a relatively long-term period of 1 year [21].
A retrospective analysis of the SMILE-4 study confirmed the good efficacy of 
zofenopril and ASA in the prevention of long-term CV outcomes also in the subgroup of
patients with HTN (n = 525, 77%), in which major CV outcomes were reported in 31% 
of zofenopril-treated patients and in 39% of ramipril-treated patients, with a 31% 
significantly (p = 0.041) lower risk with zofenopril. The superiority of zofenopril vs. 
ramipril was particularly evident in patients with isolated systolic hypertension (ISH) 
[0.48; p = 0.045]. The peculiar pharmacological characteristics of zofenopril, with its 
high efficacy on the remodeling process and on endothelial dysfunction shown in 
animal and human models, might explain its superior clinically efficacy in respect to 
ramipril [22].
The benefits of zofenopril treatment were maintained in the long term, as 
demonstrated by the results of the follow-up of the SMILE-4 study, in which zofenopril 
was superior compared to ramipril in terms of reduction of the combined endpoint of 
death and hospitalization (primary endpoint) in patients enrolled in the trial for more 
than 5 years: the primary endpoint occurred in 27.8% of patients originally randomized 
and treated with zofenopril and in 43.8% of patients treated with ramipril [OR: 0.65; p =
0.041], demonstrating that benefits of early treatment of patients with LVD after AMI 
with zofenopril are sustained over many years as compared to ramipril [23].  
The favorable effects of zofenopril treatment in patients with IHD were confirmed by
the results of the pooled data analysis of the SMILE studies. The reduction in mortality 
and morbidity observed in zofenopril-treated patients in comparison to placebo and 
other ACEIs (Fig. 2) supports the fact that additional actions of zofenopril beyond ACE 
inhibition per se contribute to its efficacy in IHD [4]. These results confirm the 
favorable effects of zofenopril treatment in patients post AMI and its long-term benefit 
in terms of prevention of CV morbidity and mortality [4].
The results of the SMILE program emphasize the importance of a personalized 
approach to patients with IHD, based on careful choice of the RAAS blocking agent, in 
order to improve the overall impact of pharmacological treatment on clinical outcomes.
Zofenopril/hydrochlorothiazide: Rationale and clinical profile
One of the most effective 2-drug antihypertensive combinations is that combining an 
ACEI and a thiazide diuretic, which involves a synergistic and opposite effect on the 
RAAS: the thiazide diuretic reduces plasma volume with a consequent increase in 
plasma renin activity, aldosterone secretion, and urinary potassium loss; the ACEI, 
blocking the RAAS, counteracts the activity triggered by the diuretic, improving the 
efficacy and tolerability of single drug components [24].
The synergistic and contrasting effects on the RAAS resulting from the concomitant 
administration of zofenopril and hydrochlorothiazide (HCTZ) may differ from those 
resulting from the combination of HCTZ with other ACEIs, depending on the 
lipophilicity of the ACEI: HCTZ could increase the tissue concentrations of zofenopril 
and induce a peculiar enhancement of the tissue activity of this lipophilic ACEI, which 
could contribute to its protective effects [24].
Zofenopril/HCTZ combination therapy was shown to be effective in the treatment of 
HTN and to be superior to monotherapy in reducing office and ambulatory BP in 
clinical studies [24]. Zofenopril/HCTZ was also shown to be more effective than the 
individual compounds as monotherapy in reducing BP over the 24 h, as confirmed by 
the higher value of smoothness index, a measure of the homogeneity of the BP control 
over 24 h, observed with zofenopril 30 or 60 mg plus HCTZ [25].
In addition, the combination of zofenopril/HCTZ was shown to provide more 
responders to treatment (DBP reduction ≥ 10 mmHg), as well as higher normalization 
rates (seated DBP < 90 mmHg) than monotherapy [26].
In addition, the fixed combination of zofenopril 30 mg plus HCTZ 12.5 mg resulted 
in improved efficacy compared with zofenopril 30 mg alone in patients with metabolic 
syndrome, in whom BP control is more difficult to achieve and who are at greater risk 
for CV events [27]. Similar results were obtained in other high-risk conditions, such as 
impaired fasting glucose or diabetes, renal impairment, or dyslipidemia [28]. 
Although zofenopril/HCTZ was proven to be effective in lowering BP in patients at 
all quartiles of CV risk, it provided greater reduction of 10-year risk of CVD in subjects 
at higher risk quartiles [28]. These data suggest the usefulness of this fixed combination 
in the treatment of patients with HTN requiring more prompt, intensive, and sustained 
BP reduction, according to guideline recommendations [28].
FDC: Z-studies 
Another effective 2-drug antihypertensive combination is that of an ARB and a thiazide 
diuretic, in which the ARB antagonizes the counter-regulatory system activity triggered 
by the diuretic [29]. 
Irbesartan, an ARB characterized by a high bioavailability, a long duration of action, 
and a small potential for pharmacological interactions, has shown a high efficacy in 
lowering BP in hypertensive patients, particularly those with renal impairment, showing
equal efficacy but better tolerability, compared to the other major antihypertensive 
classes [29].
Both zofenopril and irbesartan have been successfully employed in hypertensive 
patients in combination with a diuretic – the efficacy of zofenopril 30 or 60 mg and 
irbesartan 150 or 300 mg, both used in combination with HCTZ 12.5, was directly 
compared in the Z-studies (ZODIAC, ZENITH, ZAMES, ZEUS) (Table 2) [29–32]. 
The primary efficacy criteria were, for all studies, the effects of the drugs on office 
BP; in the ZEUS study, the effect on ambulatory BP was also assessed (through 
ambulatory BP monitoring [ABPM]). In 2 studies, ZODIAC and ZENITH, the long-
term effects of the drugs were also evaluated [33].
In the ZODIAC study, an international, multicenter, randomized, double-blind, 
parallel group study, conducted at 27 hospitals in 5 different European countries, 361 
treated hypertensive patients were randomized to 18-week treatment with zofenopril 30 
mg + HCTZ 12.5 mg or irbesartan 150 mg + HCTZ 12.5 mg once daily for 18 weeks 
[29]. Both zofenopril + HCTZ and irbesartan + HCTZ had similar effects in terms of 
office DBP/SBP reductions (17.6/21.5 mmHg vs. 15.1/20.6 mmHg; p = 0.134 for DBP 
and p = 0.691 for SBP), sitting office BP normalization (SBP < 140 mmHg and DBP < 
90 mmHg, 79.6 vs. 79.5%; p = 0.973), and 24-h DBP/SBP reductions (15.4/21.2 mmHg
vs. 16.8/23.2 mmHg; p = 0.397 for DBP and p = 0.458 for SBP). At the end of the study,
serum levels of high sensitivity C-reactive protein (an indirect marker of vascular 
inflammation) were reduced in patients treated with zofenopril (–0.52 mg/L) and 
increased in those receiving irbesartan (0.97 mg/L), with a significant difference in 
favor of zofenopril (p = 0.001). The results of the ZODIAC study suggest that, in 
previously monotherapy-treated, uncontrolled patients with hypertension, zofenopril 
30–60 mg + HCTZ 12.5 mg is as effective as irbesartan 150–300 mg + HCTZ 12.5 mg, 
with the added value of a potential protective effect against vascular inflammation [29].
The ZENITH study, a randomized, double-blind, controlled, parallel group study 
conducted in 434 essential hypertensives with additional CV risk factors and 
uncontrolled by a previous monotherapy, treated for 18 weeks with HCTZ 12.5 mg + 
zofenopril 30 or 60 mg or irbesartan 150 or 300 mg, specifically looked at the effect of 
treatment on target organ damage [30]. The antihypertensive effect was similar with the 
two combinations with no difference in the rate of responders in terms of both 24-h 
(zofenopril: 85% vs. irbesartan: 84%; p = 0.781) and office BP (zofenopril: 68% vs. 
irbesartan: 70%; p = 0.778). The proportion of patients who had regression of target 
organ damage was similar with both drugs for cardiac damage, assessed by LV mass 
index, and renal damage, evaluated by albumin/creatinine ratio or microalbuminuria. 
The percentage of patients showing regression of vascular damage, evaluated by carotid
intima/media thickness, was larger with zofenopril than with irbesartan (31.6% vs. 
16.1% reduction, respectively; p = 0.0547). No difference between the 2 drugs was 
observed in the long term: at the end of the 30-week double blind extension period no 
differences were observed in office BP response and office and 24-h BP reductions 
between the 2 treatment groups. Similarly, the long-term impact of treatment on target 
organ damage did not significantly differ between the 2 study drugs. The results of the 
ZENITH study demonstrated that the combination of zofenopril or irbesartan and HCTZ
provide similarly effective and well tolerated control of BP in hypertensive patients not 
responding to a previous monotherapy and with a high or very high CV risk profile, 
effectively delaying the progression of CV, renal, and vascular damage of HTN [30].
The ZAMES study, a multicenter, international, randomized, double-blind, parallel 
group, phase III study, conducted in 482 patients randomly allocated to a fixed-dose 
combination of zofenopril 30 mg + HCTZ 12.5 mg or irbesartan 150 mg + HCTZ 12.5 
mg once daily for a cumulative period of 24 weeks, specifically evaluated whether 
treatment with the fixed-dose combination containing a sulfhydryl ACEI is at least as 
effective as that containing an ARB in patients with metabolic syndrome and essential 
HTN, uncontrolled by previous monotherapy [31]. Baseline-adjusted DBP reductions 
were superimposable (p = 0.370) with zofenopril + HCTZ (n = 231; 9.8 mmHg) and 
irbesartan + HCTZ (n = 235; 10.4 mmHg). The same was for SBP (17.0 mmHg 
zofenopril + HCTZ vs. 18.8 mmHg irbesartan + HCTZ, p = 0.113). The rate of 
normalized and responder patients (SBP/DBP < 140/90mmHg or SBP reduction > 20 
mmHg or DBP reduction > 10 mmHg) did not differ at study end (65.8% and 77.5% 
zofenopril + HCTZ vs. 67.7% and 81.5% irbesartan + HCTZ; p = 0.695, p = 0.301). 
These results were confirmed in the 69 participants undergoing ABPM, with a 
comparable 24-h average BP reduction (BP difference between treatment: SBP: 0.1 
mmHg, p = 0.975; DBP: –0.9 mmHg, p = 0.541). Both drugs determined similar BP 
reductions also in the last 6 h of the dosing interval [31]. There were no differences in 
the effects of either combination on lipid profile or fasting blood glucose, whereas the 
reduction of the albumin/creatinine ratio was larger for irbesartan, suggesting a slight 
but significantly larger effect on renal function [31]. Thus, based on the results of the 
ZAMES study, the combination between zofenopril and HCTZ and that of irbesartan 
and HCTZ both provide similarly effective, prolonged, and well tolerated control of BP 
in high-risk hypertensive patients with metabolic syndrome [31].
The ZEUS study, an international, multicenter, randomized, double-blind, parallel-
group, phase III study, conducted in 230 patients enrolled at 24 hospitals located in 3 
different European countries, randomized to 18-week treatment with zofenopril + 
HCTZ (30 + 12.5 mg, to be up-titrated to 60 mg in uncontrolled patients after 6 or 12 
weeks) or irbesartan + HCTZ (150 + 12.5 mg, to be up-titrated to 300 mg in 
uncontrolled patients after 6 or 12 weeks), specifically looked at the effect of treatment 
in elderly (> 65 years) patients with isolated systolic HTN (ISH), untreated or 
uncontrolled by a previous monotherapy [32]. The effect on BP was the same for the 2 
drugs: daytime SBP reductions after 6 weeks (primary study end point) were similar 
with zofenopril + HCTZ and irbesartan + HCTZ (7.7 vs. 7.9, p = 0.888). Daytime SBP 
reductions were sustained during the study and were greater with low-dose zofenopril + 
HCTZ at study end (16.2 vs. 11.2 mmHg, p = 0.028). The daytime SBP normalization 
(< 135 mmHg) rate was similar under zofenopril + HCTZ and irbesartan + HCTZ at 6 
and 12 weeks, but more common under zofenopril + HCTZ at 18 weeks (68.2% vs. 
56.0%, p = 0.031). Both drugs equally reduced SBP in the last 6 h of the dosing interval 
and homogeneously reduced SBP throughout the 24 h. The results of the ZEUS study 
indicate that 18 weeks of treatment with both zofenopril 30–60 mg + HCTZ 12.5 mg 
and irbesartan 150–300 mg + HCTZ 12.5 mg was effective in reducing and controlling 
daytime SBP in elderly patients with ISH. However, when maintained at a low dose, 
long-term treatment with zofenopril plus the thiazide diuretic was superior to the 
irbesartan-based combination [32].
A pooled analysis of the results of the Z-studies (n = 1469) confirmed the efficacy of 
both combinations on office and ambulatory BPs after 18–24 weeks, with similar 
reductions over 24 h and over the last 6 h, both with the high and low dose 
combinations [33]. The analysis of data from the low-dose subgroups (corresponding to 
the currently available doses on the market) showed a higher efficacy of zofenopril 30 
mg + HCTZ 12.5 vs. irbesartan 150 mg + HCTZ 12.5 in the ZODIAC study in terms of 
office DBP reductions (19.8 vs. 14.5 mmHg, p = 0.022). Similarly, in the patients of the 
ZEUS study maintaining the low drug doses throughout the study, the magnitude of the 
daytime BP lowering was always slightly greater under zofenopril 30 mg + HCTZ 12.5 
mg than under irbesartan 150 mg + HCTZ 12.5 mg; in this study subgroup, a 
statistically significant (p = 0.028) difference in favor of zofenopril-treated patients was 
achieved at study end (16.2 vs. 11.2 mmHg) (Fig. 3). For the low-dose subgroup, also 
the percentage of patients showing daytime SBP normalization (< 135 mmHg) and 
response (SBP < 135 mmHg or reduction > 10 mmHg) at study end was significantly 
larger under zofenopril (88.9% and 91.7%) than under irbesartan (73.2% and 78.0%; p 
= 0.017 and p = 0.024, respectively) [33].
As far as the safety profile is concerned, in the Z-studies the total number of adverse 
events, as well as the proportion of treatment-related adverse events, was limited and 
similar between the 2 treatments (25.2% of patients receiving zofenopril and 21.9% of 
patients receiving irbesartan; p = 0.715) [33]. This is consistent with the safety profile of
the zofenopril + HCTZ combination derived from clinical trials, in which it was 
associated with a low percentage of treatment withdrawals [26]. Similarly, in the Z-
studies, only 66 (4.3%) patients were withdrawn from the studies because of an adverse 
event – 38 in the zofenopril (4.9%) and 28 in the irbesartan treatment group (3.6%; p = 
0.593). The most common drug-related adverse event observed under zofenopril was 
cough (1.8% of patients), whereas dizziness was the most prevalent drug adverse 
reaction in irbesartan-treated patients (1.4%) [33].
All these results support the usefulness of zofenopril + HCTZ FDC in the treatment
of high-risk hypertensive patients or patients not adequately controlled by mono-
therapy: a further advantage of zofenopril in these patients is the lack of interaction 
with ASA, which may reduce the benefit of treatment with ACEIs in patients with 
chronic coronary heart disease, including those with HF [34]. This is of particular 
interest in complicated patients because antiplatelet therapy, in particular low-dose 
ASA, is recommended for secondary prevention in hypertensive patients [1].
Treatment adherence
Medication adherence is a growing concern to clinicians and healthcare systems 
because of mounting evidence that nonadherence is very frequent and associated with 
adverse outcomes and higher costs of care. Nonadherence to medications is common for
patients with CVDs; in particular, about half of all patients prescribed antihypertensive 
medications have been found to stop taking them within 1 year of the initial prescription
[35], with an average non-adherence rate in patients with resistant HTN of 31.2% [36]. 
This has a negative impact on treatment effectiveness because high adherence (defined 
as medication possession ratio of 80% to 100%) to antihypertensive medications has 
been shown to be associated with a higher probability of BP control compared with 
medium or low levels of adherence [35]. 
The reasons for non-adherence belong to different categories, many of which apply 
to HTN; the World Health Organization has categorized potential reasons for 
medication nonadherence into 5 broad groupings that include patient-, condition-, 
therapy-, socioeconomic-, and health system-related factors [35]. For therapy-related 
factors, the complexity of the regimen and the perceived or experienced side effects can 
impact adherence [35].
Side effects are a big problem in anti-hypertensive treatment: a meta-analysis of 354 
randomized double-blind placebo controlled HTN trials including 40,000 treated 
patients and 16,000 patients given placebo showed that most anti-hypertensive classes 
(except ACEIs) are associated with dose-related side effects, which might reduce 
adherence [37]. The choice of antihypertensive regimen should therefore be based on a 
careful evaluation of both the efficacy and tolerability profile of available drugs, in 
order to minimize side effects and maximize adherence, thus optimizing treatment 
efficacy.
Combinations of 2 antihypertensive drugs at fixed doses in a single tablet may be 
recommended and favored in chronic conditions like HTN, because reducing the 
number of daily pills improves adherence: non-compliance to medication regimens is 
reduced by 24–26% with fixed-dose combination regimens, which provide a strong 
armamentarium in chronic disease management [38]. Simplifying therapeutic regimens 
by using effective and well tolerated fixed dose combinations is therefore a successful 
strategy to improve adherence to anti-hypertensive therapy: the combination of 
medications targeting multiple mechanisms reduces the heterogeneity of the BP 
response to initial treatment and provides a steeper dose response than with escalating 
doses of monotherapy [1]. Moreover, whereas reductions in BP with drugs in 
combination are additive, adverse effects are less than additive [37].
Conclusions 
Angiotensin converting enzyme inhibitors are a heterogeneous class of CV 
drugs, exerting beneficial effects in patients with, or at risk of, CVD. Differences in the 
pharmacological profile of ACEIs can significantly impact clinical efficacy. SH-donor 
ACEIs are characterized by important ancillary properties (greater tissue selectivity, 
anti-oxidant effect, direct and indirect increase of NO availability). Zofenopril is an 
ACEI with unique properties due to its sulfhydryl group (high lipophilicity, free radical 
scavenging properties, and selective cardiac ACE inhibition, cardio-protective activity), 
which can be of particular value in patients with coronary artery disease. The positive 
impact of the cardio-protective effect of zofenopril on clinical outcomes has been 
extensively documented by the SMILE project, including several clinical trials in 
patients with different conditions of myocardial ischemia treated with zofenopril. On the
other hand, the results of Z-studies suggest that the fixed combination of zofenopril and 
HCTZ, thanks to its ancillary features (anti-inflammatory action, regression of organ 
damage, metabolic neutrality) and good tolerability profile, may have a relevant place in
the treatment of high-risk or monotherapy-treated, uncontrolled hypertensive patients 
requiring a more prompt, intensive and sustained BP reduction, in line with the 
recommendations of current guidelines (central illustration). A “patient-oriented” 
integration of guidelines, based on a careful consideration of the differences across 
antihypertensive drugs, patient’s characteristics, approach to treatment, and additional 
risk factors, is a mandatory strategy for the future treatment of HTN, taking into 
consideration the complexity of the condition beyond BP.
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Table 1. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) 
program.
Study [ref] Main features
SMILE Pilot Study 
[17]
204 non-thrombolyzed patients
Zofenopril vs. standard treatment
Safety assessment
SMILE Study [18] 1556 non-thrombolyzed patients
Zofenopril vs. placebo
6-week incidence of death or severe CHF
1-year mortality rate
SMILE-2 Study [19] 1024 thrombolyzed patients
Zofenopril vs. lisinopril




349 thrombolyzed patients with preserved left ventricular EF 
Zofenopril vs. placebo
6-month global ischemic burden
SMILE-4 Study [21] 771 patients with systolic left ventricular dysfunction (EF < 45%)
Zofenopril + ASA vs. ramipril + ASA
1-year combined occurrence of death or hospitalization for 
cardiovascular causes
ASA — acetylsalicylic acid; EF — ejection fraction
Table 2. The Z studies
Study [reference] Main features
ZODIAC [29] 361 patients with uncontrolled BP 
Zofenopril + HCTZ vs. irbesartan + HCTZ
Office diastolic BP changes after 18 weeks
ZENITH [30] 462 patients with uncontrolled blood pressure
Zofenopril + HCTZ vs. irbesartan + HCTZ
Office diastolic BP response after 18 weeks
ZAMES [31] 482 patients with uncontrolled blood pressure
Zofenopril + HCTZ vs. irbesartan + HCTZ
Office diastolic BP changes after 24 weeks
ZEUS [32] 230 patients with uncontrolled isolated systolic hypertension
Zofenopril + HCTZ vs. irbesartan + HCTZ
Mean daytime systolic BP changes after 6 weeks
BP — blood pressure; HCTZ — hydrochlorothiazide
Figure 1. Effect of zofenopril on H2S and nitric oxide (NO) bioavailability (reproduced 
from [10]); ACEI — angiotensin converting enzyme inhibitors; eNOS — endothelial 
nitric oxide synthase.
Figure 2. Cumulative survival without events during the first 42 days of treatment with 
zofenopril (n = 1808), placebo (n = 951), lisinopril (n = 520) or ramipril (n = 351) in the
Survival of Myocardial Infarction Long-term Evaluation (SMILE) program. Data are 
shown by pooling together data obtained under lisinopril and ramipril (other angiotensin
converting enzyme inhibitors, A) and separately for each treatment group (B) 
(reproduced from [4]); CV — cardiovascular.
Figure 3. Mean changes (Δ) with treatment (and 95% confidence interval) in office 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the ZODIAC (a) 
and ZENITH study (b), and mean daytime SBP changes in the ZEUS study (c), in the 
subgroup of patients receiving the low drug doses during the study. The p values refer to
the statistical significance of the between-treatment difference (reproduced from [33]); 
BP — blood pressure; HCTZ — hydrochlorothiazide.
Central illustration. The role of zofenopril in blood pressure control and 
cardioprotection; ACEI — angiotensin converting enzyme inhibitors; AMI — acute 
myocardial infarction; BP — blood pressure; CV — cardiovascular; HCTZ — 
hydrochlorothiazide; LV — left ventricular; LVEF — left ventricular ejection fraction; 
NO — nitric oxide; RAAS — renin–angiotensin–aldosterone system.




